epristeride

01/01/2002 - "To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH). "
01/01/2002 - "[The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia]."
04/29/1999 - "Epristeride, a 5alpha-reductase inhibitor, decreases prostate size and improves symptoms in men with benign prostatic hyperplasia. "
04/29/1999 - "The mechanism of epristeride against benign prostatic hyperplasia."
11/01/1998 - "To evaluate the genetic effects of epristeride (Epr), a new prospective drug for treating benign prostatic hyperplasia. "

03/01/2001 - "To study the molecular mechanism of rat prostate atrophy induced by epristeride. "
05/01/2001 - "Atrophy and apoptosis in ventral prostate of rats induced by 5alpha-reductase inhibitor, epristeride."
05/01/2001 - "Apoptosis induced by epristeride was one of mechanisms in the treatment of benign prostatic hyperplasia and the activity of ACP could be used as a marker of prostate atrophy."
11/01/2001 - "In our opinion, the effect of epristeride on rat prostatic atrophy might be mediated via local growth factor(s)."
05/01/2001 - "To study molecular mechanism of epristeride in the treatment of benign prostatic hyperplasia and discuss the possibility of using prostate acid phosphatase (ACP) as a marker of the atrophy of prostatic gland in vivo. "

08/01/2000 - "Epristeride and casodex showed a dose-dependent promoting effect on rat ventral prostate carcinogenesis. "
08/01/2000 - "The objective of this study was to determine the effects of androgen depletion by 5alpha-reductase inhibitor (eg epristeride), pure antiandrogen (eg casodex) or C17-20 lyase inhibitor (eg YM116) on rat prostate carcinogenesis induced by administration of 3,2'-dimethyl-4-aminobiphenyl (DMAB). "

01/01/1992 - "Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657."
01/01/1992 - "By contrast, the rat R-3327 H prostatic cancer has a much higher level of tissue 5 alpha-reductase activity, and neither tumor DHT content nor growth of the tumor was inhibited by treatment with SK&F 105657. "
01/01/1992 - "The response of two androgen-responsive rat prostatic cancers (i.e., Dunning R-3327 H and G sublines) and one androgen-responsive human prostatic cancer (i.e., PC-82) to the 5 alpha-reductase inhibitor, SK&F 105657, was tested in vivo. "
01/01/1992 - "In order to achieve such a DHT reduction in tumor tissue, prostatic cancers with low 5 alpha-reductase activity could be treated with SK&F 105657 on a dose regimen that lowers serum DHT to surgical castration levels, while concomitantly inhibiting the already low tumor tissue 5 alpha-reductase activity."

01/01/1992 - "The rat R-3327 G tumor and the human PC-82 tumor have a low to undetectable level of tissue 5 alpha-reductase activity and both responded to SK&F 105657 treatment with a reproducible inhibition of tumor growth. "
01/01/1992 - "By contrast, the rat R-3327 H prostatic cancer has a much higher level of tissue 5 alpha-reductase activity, and neither tumor DHT content nor growth of the tumor was inhibited by treatment with SK&F 105657. "
01/01/1992 - "In order to achieve such a DHT reduction in tumor tissue, prostatic cancers with low 5 alpha-reductase activity could be treated with SK&F 105657 on a dose regimen that lowers serum DHT to surgical castration levels, while concomitantly inhibiting the already low tumor tissue 5 alpha-reductase activity."